Ivonescimab Cuts Death Risk 34% in Chinese Lung Study
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Ivonescimab reduced the risk of death in squamous non‑small cell lung cancer patients by 34% versus standard therapy in a trial conducted entirely in China.
- Akeso Therapeutics ran the phase‑III study in China and presented the results at the American Society of Clinical Oncology annual meeting.
- Summit Therapeutics is developing ivonescimab outside China; co‑CEO and chairman Robert Duggan said the data demonstrate a very valuable product in early stages.
- Oncologists said the survival benefit exceeded expectations, sparking debate on China’s role in drug development and the future of cancer therapies.
Why it matters: Patients with squamous NSCLC gain a clear survival advantage, while Summit Therapeutics' product pipeline gains a strong efficacy signal that boosts its early‑stage commercial outlook; the trial also showcases China's capacity to generate high‑impact oncology data.
